Literature DB >> 11533093

Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group.

D M Green1, N E Breslow, J B Beckwith, M L Ritchey, R C Shamberger, G M Haase, G J D'Angio, E Perlman, M Donaldson, P E Grundy, R Weetman, M J Coppes, M Malogolowkin, P Shearer, P Coccia, M Kletzel, P R Thomas, R Macklis, G Tomlinson, V Huff, R Newbury, D Weeks.   

Abstract

PURPOSE: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. PATIENTS AND METHODS: A study of nephrectomy only for the treatment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower.
RESULTS: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%.
CONCLUSION: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.

Entities:  

Mesh:

Year:  2001        PMID: 11533093     DOI: 10.1200/JCO.2001.19.17.3719

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

1.  Barriers to the enrollment of children in the Children's Oncology Group study of very low risk Wilms tumor: a report from the Children's Oncology Group.

Authors:  Conrad V Fernandez; Ning Li; Elizabeth A Mullen; Paul E Grundy; Elizabeth J Perman; Robert C Shamberger; Peter F Ehrlich; Jeffrey S Dome
Journal:  J Pediatr Hematol Oncol       Date:  2011-10       Impact factor: 1.289

Review 2.  Current management of wilms' tumor.

Authors:  Leah Nakamura; Michael Ritchey
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

3.  WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

Authors:  Elizabeth J Perlman; Paul E Grundy; James R Anderson; Lawrence J Jennings; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; E Cristy Ruteshouser; Vicki Huff
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

4.  Partial and radical nephrectomy in children, adolescents, and young adults: Equivalent readmissions and postoperative complications.

Authors:  M Hassan Alkazemi; Zachary R Dionise; Ruiyang Jiang; Steven Wolf; Gina-Maria Pomann; Elisabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Pediatr Surg       Date:  2019-05-31       Impact factor: 2.545

5.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

6.  Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.

Authors:  Peter F Ehrlich; James R Anderson; Michael L Ritchey; Jeffrey S Dome; Daniel M Green; Paul E Grundy; Elizabeth J Perlman; John A Kalapurakal; Norman E Breslow; Robert C Shamberger
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

Review 7.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

Authors:  Simone T Sredni; Samantha Gadd; Chiang-Ching Huang; Norman Breslow; Paul Grundy; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

Review 9.  Current and emerging chemotherapy treatment strategies for Wilms tumor in North America.

Authors:  Eric J Gratias; Jeffrey S Dome
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Wilms' tumor: An update.

Authors:  Hemant B Tongaonkar; Sajid S Qureshi; Purna A Kurkure; Mary-Ann A Muckaden; Brijesh Arora; Thyavihalli B Yuvaraja
Journal:  Indian J Urol       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.